ABSTRACT
INTRODUCTION
Organised cytology-based cervical screening programmes using physician-collected cervical scrapes have led to a substantial decrease in cervical cancer incidence and mortality in highincome countries 1 . However, a considerable subset of women does not attend cervical screening (non-attendees), which compromises the effectiveness of the screening programme 2 . Previous studies have shown that offering self-sampling of cervico-vaginal specimens (self-samples) for high-risk human papillomavirus (hrHPV) testing (hrHPV self-sampling) to non-attendees increases the attendance to cervical screening. Up to 30% of the invited non-attendees returned their self-sample to the laboratory for hrHPV testing [3] [4] [5] [6] . Importantly, the diagnostic accuracy of hrHPV testing on self-samples for cervical intraepithelial neoplasia grade 3 and cervical cancer (CIN3+) is similar to hrHPV screening of physician-collected cervical scrapes 7, 8 .
Therefore, offering hrHPV self-sampling as an alternative to conventional scrapes has just been implemented in the new HPV-based cervical screening programme in the Netherlands. Partial substitution of hrHPV testing on physician-collected scrapes in cervical screening programmes by hrHPV self-sampling can be envisioned in the near future.
Although hrHPV testing has a higher sensitivity for CIN3+ compared with cytology, its 3% to 5% lower specificity for CIN3+ necessitates the use of a triage test to distinguish women with clinically relevant disease from those with irrelevant, transient hrHPV infections to prevent overreferral and overtreatment. Currently, cytology is the most widely accepted triage tool. Because cytology cannot be reliably performed on self-sampled material [9] [10] [11] , women with hrHPV-positive self-samples need to visit a physician for an additional cervical scrape for cytology. This may lead to loss to follow-up, delay the diagnostic track and is less feasible in low-income countries given the lack of adequate infrastructure and limited number of trained practitioners 8, 12, 13 .
Therefore, molecular triage testing directly applicable to self-sampled material from hrHPVpositive women is preferred.
We and others have shown that DNA methylation analysis of tumour-suppressor genes on selfsamples is well feasible and effective to detect CIN3+ using quantitative methylation-specific PCR (qMSP) [12] [13] [14] [15] [16] . DNA methylation analysis has already shown competitive clinical performance versus other triage options in cervical scrapes, whereas improvements in performance on selfsamples are conceivable. Previous findings have shown that DNA methylation markers originally discovered in tissue specimens and tested on hrHPV-positive cervical scrapes are not necessarily of clinical value when applied to hrHPV-positive self-samples
In this study, we describe the identification and validation of a DNA methylation classifier for the detection of CIN3 and cervical cancer in hrHPV-positive self-samples. A genome-wide DNA methylation marker discovery for CIN3 detection was performed using the Infinium 450K
BeadChip array to 72 hrHPV-positive self-samples from a screening cohort of non-attendees.
The identified candidate DNA methylation markers were evaluated by multiplex qMSP in unique, large series of lavage-based (n=245; further referred to as "lavage self-samples") and brushbased (n=246; further referred to as "brush self-samples") self-samples from screening cohorts of non-attendees to build an optimal DNA methylation classifier for detection of CIN3 that is applicable to self-samples of both devices. The clinical performance of the obtained DNA methylation classifier was subsequently validated by multiplex qMSP on an independent series of lavage (n=199) and brush (n=287) self-samples.
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MATERIALS AND METHODS
Clinical specimens
Discovery set: case-control series for DNA methylation marker discovery screen
For genome-wide DNA methylation marker discovery for CIN3 detection, hrHPV-positive lavage self-samples collected using the Delphi Screener (Delphi Bioscience) were obtained from a screening cohort of non-attendees (PROHTECT-1 trial 3 ; NTR792; n=72; Fig. 1 Building set: case-control series to build a DNA methylation classifier
To build a DNA methylation classifier for CIN3 detection, both hrHPV-positive lavage selfsamples (n=245; PROHTECT-1 trial 3 ; excluding samples used for the discovery screen) and brush self-samples collected using a Viba-Brush® (Rovers Medical Devices B.V., Oss, The
Netherlands; n=246; PROHTECT-2 trial 4 ; NTR1851) were obtained from screening cohorts of non-attendees who reached a study endpoint and all of which were not preselected ( Fig. 1; building a DNA methylation classifier; Supplementary Fig. S1 ). Validation set: independent series to validate the DNA methylation classifier
To validate the clinical performance of the DNA methylation classifier, independent series of both hrHPV-positive lavage (n=199) and brush (n=287) self-samples, all of which were not preselected, were used ( Fig. 1 ; Validation of DNA methylation classifier; Supplementary Fig. S1 ).
For lavage self-samples, hrHPV-positive samples collected using the Delphi Screener (Delphi Bioscience) were obtained from a screening cohort of non-attendees who reached a study endpoint in the PROHTECT-3 trial (methylation-arm; NTR2606) 12 . Detailed characteristics of study design, clinical specimens, inclusion criteria and follow-up procedures have been described previously 12 .
Half of the available samples in this trial were randomly chosen for evaluation in the current study. These were supplemented with an independent series of four lavage self-samples from women with SCC who participated in the PROHTECT- For brush self-samples, hrHPV-positive samples collected using the Evalyn® Brush (Rovers Medical Devices B.V., Oss, The Netherlands) were obtained from a screening cohort of nonattendees who reached a study endpoint in the PROHTECT-3B trial (NTR3350) 18 . Detailed characteristics of study design, clinical specimens, inclusion criteria and follow-up procedures have been described previously 18 . These were supplemented with an independent series of four brush self-samples from women with SCC and one brush self-sample from a woman with adenocarcinoma in situ (ACIS) who participated in the PROHTECT-2 trial 4 Table S1 . HrHPV positivity was determined for all samples. HrHPV genotypes were defined in a subset of the classifier building set only. In each multiplex qMSP assay, three targets and the housekeeping gene β-actin (ACTB) were combined as described before 19 . Target DNA methylation values were normalised to reference gene ACTB and the calibrator using the comparative C t method (2 -ΔΔCt x 100) to obtain ΔΔC t ratios 20 . The ΔΔC t ratios were square root-transformed. Only samples for which sufficient DNA material was available and which achieved an ACTB C t value < 30 were included.
Statistical analyses
Discovery screen: genome-wide DNA methylation array data After preprocessing of Infinium data, we applied adaptive group-regularised logistic ridge regression (GRridge) 21 . We incorporated auxiliary information (referred to as co-data) in building the GRridge classification model, namely P values from a similar study in cervical tissue specimens using the same array platform (Farkas and colleagues 22 ) and standard deviation (sd) of each probe in the current dataset. Using informative co-data has been shown to enhance the identification of valuable markers in rather impure samples, such as selfsamples ( Supplementary Fig. S3 ). More details regarding the GRridge model by incorporating such information are provided in Supplementary Methods and elsewhere 21 . Post hoc forward selection was applied to the GRridge model to render a model of DNA methylation markers.
The performance of the GRridge model was visualised by a receiver operating characteristics (ROC) curve, obtained by leave-one-out cross-validation, and quantified by area under the curve (AUC). Predicted probabilities, representing the risk for an underlying CIN3, were calculated using the GRridge model. Hierarchical clustering of the 28 DNA methylation markers was performed to further select the genes that were most discriminative between CIN3 and hrHPV-positive controls.
Building and validation of DNA methylation classifier: qMSP data
To compare DNA methylation levels between two groups (hrHPV-positive controls and CIN3), the Wilcoxon rank-sum test (two-sided) was applied on the square root-transformed ΔΔC t ratios. Statistical significance was set at P < 0.05.
To build a DNA methylation classifier, classical logistic regression analysis was performed on qMSP data to select relevant DNA methylation markers for CIN3 detection in both lavage and brush self-samples (detailed description in Supplementary Methods and Supplementary Fig. S4 ).
In brief, logistic regression analysis followed by stepwise selection and backward elimination was performed on the combination of lavage and brush self-sample datasets (to encourage overlap) to obtain an initial marker panel of two DNA methylation markers for both self-sample types. Forward selection on the separate lavage and brush datasets suggested the addition of a third DNA methylation marker, which was particularly relevant for the brush dataset, without harming the performance in the lavage dataset. Because DNA methylation in CpG islands has been shown to increase with age 23 , we included age as a factor in the DNA methylation classifier.
Supplementary Table S2 shows the P value and contribution (coefficient/sd) of age and the third DNA methylation marker ST6GALNAC5 in the 3-gene methylation classifier. These two factors were included in the classifier because exclusion of age and ST6GALNAC5 resulted in a lower performance in particularly the brush self-samples. Predicted probabilities and 95% confidence interval (CI) were calculated for all analysed samples using the logistic regression models of the DNA methylation classifier for lavage and brush self-samples. The clinical performance of the logistic regression models in both classifier building and validation sets was visualised by an ROC curve and evaluated by AUC calculation. The ROC curves show the sensitivity and specificity for the complete spectrum of different thresholds in predicted probabilities using the logistic regression models. A threshold was fixed for predicted probabilities corresponding to 80% specificity (lavage self-samples: 0.053; brush self-samples: 0.240) based on the classifier building set and subsequently evaluated in the independent validation set for CIN3 sensitivity and specificity. In addition, the DNA methylation classifier at a fixed threshold was applied on self-samples from women with CIN2, SCC and ACIS/AdCA to evaluate the positivity rates in these disease categories. A classification and regression tree (CART) algorithm, which renders a DNA methylation classifier using marker-based cutoffs, was built for comparison with the continuous values obtained by regression. For the details of the CART method, see
Supplementary Methods.
RESULTS
An overview of the study design is given in Fig. 1 . Table 1 ; Supplementary Fig. S5 ). Evaluation of the DNA methylation profiling data from four hrHPV-positive lavage self-samples from women with SCC confirmed high DNA methylation levels for all these 12 DNA methylation markers ( Fig. 2B ; Supplementary Fig. S5 ). Building a DNA methylation classifier using hrHPV-positive lavage and brush self-samples Next, the 12 most discriminative DNA methylation markers from the discovery screen were further analysed using multiplex qMSP in large series of hrHPV-positive lavage self-samples (n=245) and brush self-samples (n=246) from women with and without CIN3 from two screening cohorts ( Fig. 1 ; building a DNA methylation classifier). In both lavage and brush selfsamples, all genes except ACAN (in lavage only; P < 0.05) showed significantly increased DNA methylation levels (P < 0.001) in self-samples from women with CIN3 compared with hrHPVpositive controls (Fig. 3) . The samples are ordered by predicted probability. The 12 DNA methylation markers above the black line showed the most discriminative DNA methylation profile between women with and without CIN3.
Building a DNA methylation classifier (12 markers)
Multiplex qMSP
(B) DNA methylation data of self-samples from women with SCC (red; n=4).
To build an optimal DNA methylation classifier for detection of CIN3, which is applicable to different self-sample types, logistic regression analysis followed by stepwise selection and backward elimination was performed on the combined dataset of lavage and brush self-sample qMSP results (see Materials and Methods, Supplementary Methods and Supplementary Fig.   S4 ). This revealed a 3-gene methylation classifier for CIN3 detection in both self-sample types, consisting of ASCL1, LHX8 and ST6GALNAC5 (Supplementary Fig. S4 ; Supplementary Table S2) . x axis) and (B) brush self-samples from hrHPV-positive controls (n=174) and women with CIN3 (n=72;
x axis). The three genes left of the black line are included in the 3-gene methylation classifier. * P < 0.05; *** P < 0.001; NS: not significant.
Validation of DNA methylation classifier
To validate the clinical performance of the 3-gene methylation classifier, an independent, large series of hrHPV-positive lavage self-samples (n=199) and brush self-samples (n=287) was analysed by multiplex qMSP ( Fig. 1 ; Validation of DNA methylation classifier). Solely hrHPVpositive controls and CIN3 from independent screening cohorts were used for validation of the 3-gene methylation classifier. This showed a comparable clinical performance for CIN3 detection as observed in the above-described classifier building set, in both hrHPV-positive lavage (AUC=0.88) and brush (AUC=0.90) self-samples ( Fig. 4A and B, grey lines) . The predefined threshold corresponding to an 80% specificity in the classifier building set (see above) was applied to this validation set. This resulted in a CIN3 sensitivity of 74% (26 of 35) in lavage self-samples and 88% (49 of 56) in brush self-samples, at 79% and 81% specificity in hrHPV-positive controls, respectively ( Supplementary Fig. S6 ). To confirm these findings, we Previous publications showed that CIN lesions detected by DNA methylation analysis do not completely overlap with those detected by cytology 24 . In fact, DNA methylation analysis tends to preferably detect cervical cancer and advanced high-grade precursor lesions, defined as CIN2/3 associated with a persistent hrHPV infection of ≥ 5 years. Women with advanced CIN2/3 are presumed to have a high short-term progression risk to cancer and are therefore in need of immediate referral and treatment 24, 25 . Cytology on the other hand detects both early and advanced CIN lesions with a moderate sensitivity of 65% to 80% and cannot be reliably applied to self-samples, requiring a visit to the physician [9] [10] [11] . DNA methylation markers are applicable To select the most discriminatory DNA methylation markers for CIN3 from our discovery screen on hrHPV-positive self-samples, which are rather impure due to an overrepresentation of non-disease-related cells, we applied our recently proposed GRridge model 21 . This method enables objective use of co-data and was shown to potentially outperform other prediction methods ( Supplementary Fig. S3 ) 26 . In particular publicly available DNA methylation data from relatively pure cervical tissue specimens, obtained by the same array platform, proved to be useful co-data 22 . The validity of this approach is supported by the identification of the three DNA methylation classifier genes that have all been previously described in DNA methylation studies on cervical cancer 22, 27, 28 . The combination of GRridge (on array data) and classical logistic regression analysis (on qMSP data) enabled us to build a highly discriminative methylation classifier for CIN3 detection consisting of ASCL1, LHX8 and ST6GALNAC5. The narrow range of the 95% CI of the predicted probabilities (i.e. the methylation classifier value; range, 0-1) in both lavage and brush self-samples supports a good representation of the disease state (case vs. control) in the population by the 3-gene methylation classifier ( Supplementary Fig. S10 ).
Comparison of the three markers in HPV16-positive self-samples to self-samples positive for other hrHPV types (non-HPV16), in the subset of samples with HPV typing information, revealed no significant difference in DNA methylation levels in both lavage and brush selfsamples, except for LHX8 in HPV16 versus non-HPV16 controls of lavage self-samples (P value = 0.03; Supplementary Fig. S11 ).
ASCL1, achaete-scute family bHLH transcription factor 1, is a proneural transcription factor and functions as a main regulator of differentiation in neurogenesis 29 . LHX8, LIM homeobox 8, is a highly conserved transcription factor regulating cell fate in neurogenesis, tooth morphogenesis and oogenesis 30 . ST6GALNAC5, ST6 N-Acetylgalactosaminide Alpha-2,6-Sialyltransferase 5, is a transmembrane sialyltransferase involved in the biosynthesis of gangliosides on the cell surface 31 . Next to cervical cancer, LHX8 methylation has been detected in breast cancer 32 , ST6GALNAC5 methylation has been described in colorectal cancer studies 33 and ASCL1 methylation has been detected in oral and colorectal cancer 34, 35 .
Of the previously described DNA methylation markers tested in self-samples [12] [13] [14] 17, 24 , the DNA methylation panel FAM19A4/miR124-2 showed the best clinical performance in a large screening cohort. Analysis of the same study cohorts as used in the present study showed a CIN3+ sensitivity of 71% in lavage and 69% in brush self-samples at a specificity of 68% and 76%, respectively 14 . Within the CIN3+ group, 68% of CIN3 and all cancers were detected in both self-sample types. Other DNA methylation marker panels, such as JAM3/EPB41L3/TERT/ C13ORF18, have only been analysed in small selected series of self-samples 15, 16 . A combination of DNA methylation markers with HPV16/18 genotyping results in higher sensitivities compared with solely DNA methylation, however at the cost of severe lower specificities due to detection of early CIN2/3 14, 36 . Our 3-gene methylation classifier shows a better sensitivity for CIN3 than other assays in both lavage (74%) and brush (88%) self-samples in a similar screening population, at a higher specificity of 79% and 81%, respectively. These findings emphasise the validity and importance of our approach to perform the DNA methylation marker discovery directly on self-sampled material. Furthermore, the 3-gene methylation classifier detected all self-samples from women with SCC. Importantly, all self-samples from women with SCC showed very high predicted probabilities (median, 1.00; range, 0.54-1.00), which accentuates the value of our 3-gene methylation classifier for detection of cervical cancer. In addition, all self-samples from women with ACIS and AdCA scored DNA methylation-positive, indicating that glandular lesions are also detected by our 3-gene methylation classifier. Nevertheless, further evaluation of cervical glandular lesions and other rare cervical cancer types is warranted.
A limitation of our study is that we used cohorts of non-attending women. Therefore, further confirmation in a regular population-based population is warranted. In addition, the Infinium 
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SUPPLEMENTARY FIGURES AND TABLES
Classifier building set PROHTECT-1 hrHPV-positive lavage self-samples n=757
Exclusion n=512 -No study endpoint or follow-up available n=380 -Histological endpoint CIN2 or Cancer n=28 -Used in discovery screen n=68 -Insufficient material available n=36
Final study population n=245 -≤CIN1 or pap1/hrHPV-negative in fu n=214 -CIN3 n=31
Validation set PROHTECT-3 hrHPV-positive lavage self-samples n=515 qMSP dataset 12 markers
3-gene methylation classifier ASCL1, LHX8, ST6GALNAC5
Lavages Brushes CIN3 with HPV16 and n=10 CIN3 with non-HPV16. * P < 0.05; NS: not significant. 
Supplementary
SUPPLEMENTARY METHODS
Infinium HumanMethylation450 BeadChip data preprocessing
Probes which, (i) showed a low bead count (< 3 in at least 5% of samples), (ii) had a detection As an extra filter, we selected probes that (i) were related to a gene according to the Illumina annotation file (v1.2), (ii) were related to a CpG-island, -shore or -shelf according to the Illumina annotation file (v1.2) and (iii) showed increased methylation in CIN3 compared with hrHPVpositive controls (difference in β-value ≥ 0.1) in an independent tissue-based study 3 .
DNA isolation, hrHPV testing and bisulphite treatment
DNA from self-samples was isolated using the NucleoMag 96 Tissue kit (Macherey-Nagel, Düren, Germany) and a Microlab Star robotic system (Hamilton, Martinsried, Germany) according to the manufacturer's protocol. DNA concentration was measured using the NanoDrop ND-1000
(Thermo Scientific, Waltham, MA, USA). In PROHTECT-1 and PROHTECT-2 trials, hrHPV detection was performed by Hybrid Capture-2 (HC2; Qiagen, Hilden, Germany) as described previously 4, 5 . HrHPV types were determined in a subset of PROHTECT-1 and PROHTECT-2 samples using the GP5+/6+ RLB system 6 . Samples from the PROHTECT-3 and PROHTECT-3B trials were tested for hrHPV by GP5+/6+ PCR using the Diassay EIA HPV GP HR kit (Diassay, Voorburg, The Netherlands) as described previously 7, 8 . HrHPV detection in samples from the X15MET study was performed by the HPV-Risk assay (Self-screen B.V., Amsterdam, The Netherlands) 9 . Prior to DNA methylation analysis, isolated DNA was bisulphite-converted using the EZ DNA Methylation kit (Zymo Research, Orange, CA, USA).
DNA methylation analysis by multiplex qMSP
For multiplex qMSP, EpiTect MethyLite Master Mix (Qiagen), 50ng of bisulphite-converted DNA and 100-300nM of each primer and fluorescent dye-labelled probe was used. Primer and probe information is shown in Supplementary Table S1. All multiplex qMSP analyses were performed on the ViiA7 (Applied Biosystems, Foster City, CA, USA). A plasmid containing the amplicon sequences of all targets and ACTB, was used as calibrator. This calibrator functions as a technical quality control and was used to calculate ΔΔC t ratios. Cycle threshold (C t ) values were measured at a fixed fluorescence threshold. All lab work was performed blinded to the results.
High-dimensional data analysis on DNA methylation array data
We applied adaptive group-regularised (logistic) ridge regression 10, 11 . GRridge can be regarded as a weighted regression for omics data. As in commonly used ridge or lasso models, regression coefficients are down-weighted ('penalised') to account for the high-dimensionality of the data.
However, our approach allows the use of prior information ('co-data') on the genomic variables to differentiate the weights, which can come from internal and external sources. Unlike metaanalysis, the co-data complements the primary study data; the latter will still be the main driver behind the classifier. Moreover, the co-data are only required during training of the classifier, not when applying the classifier to new (test) samples.
The weights are estimated in an objective, unbiased way using so-called empirical Bayes techniques 10 . Roughly, this measures how relevant the co-data is for the primary data at hand, and if so, allows more skewed weights across groups of variables. If the co-data is not relevant, it will automatically assign flat weights, which means that the performance then converges to the classical logistic ridge regression model. In our study, we incorporated co-data from external and internal sources. For the first co-data, we used information from a similar DNA methylation study in cervical cancer 3 . For each and every probe in this external set, we computed a P value from the moderated t-statistic 12 . Next, we grouped the probes in our primary dataset based on these P values into a partition of 100 groups and forced monotony for the group-specific penalties, meaning that a group of variables with higher P values than another group will receive a penalty that is at least as high as that of the other group. This highly stabilises the weights. If the partition is informative to the primary data set, the probes with a low P value (high DNA methylation signal) would receive more weight. As second source of co-data, we used the standard deviation (sd) of the probes in our primary dataset. The sd was calculated across samples, ignoring the class labels (or responses). The use of sd as co-data was motivated in 10 .
Having estimated the group-penalties, a weighted logistic regression is used as a classifier.
We showed that the weights aid in improving predictive performance in particular when a parsimonious model (with few genomics variables) is desired, as is often the case in clinical settings. The philosophy is that the weights help enhancing the variables truly related to the outcome while suppressing the false variables ( Supplementary Fig. S3 ). It is important to mention that the co-data should be defined independently from the response in the training set, in order to avoid overfitting.
Logistic regression analysis to build a DNA methylation classifier
Here, we employed the classical logistic regression method to solve the binary classification case with the previously selected methylation targets from the GRridge model.
On each brush ( ℬ )-and lavage (ℒ ) self-samples dataset, we built a (classical) logistic regression model. To compensate for increased DNA methylation due to age, the regression models were corrected by Age. For an independent response from a sample on the ℬ dataset (denoted as 
where is the probability of a woman to be diagnosed with a CIN3, and; "# is the ΔΔC t ratios of methylation marker from sample (transformed to the square root scale).
We checked interaction effects in the logistic regression model of each dataset. First, omnibus test for the interaction effects was conducted. A likelihood-ratio test was applied to test the difference of fits from two nested models, i.e. a model with all possible interaction terms and a model with main effects only. This test evaluates whether adding interaction terms significantly improves the performance of the model.
As both datasets agreed that interaction terms did not significantly improve the goodness-offit of logistic regression models (P value=0.136 and 0.199 for brush and lavage self-samples dataset, respectively), we further processed the predictive modeling by neglecting interaction terms on the model.
We built logistic regression models such that the selected markers improved the performance of regression models in both datasets. As a starting point, we incorporated all markers ( = 12 ) to model (1) and model (2) . We then estimated joined-AIC (Akaike information criterion) from both models by: In addition, a standard AIC-based stepwise selection algorithm (as implemented in the 'stepAIC' function of R software) was applied to the regression models to allow additional relevant markers for CIN3 detection in either of the two separate datasets, as motivated in the main article.
Classification and regression tree
We applied an algorithm-based method, named classification and regression tree (CART) method, to do a binary classification on healthy control (hrHPV-positive controls) and case (CIN3) samples in the classifier building set. A tree model was grown by applying gini index as a measurement of node impurity. Further, once a complete model was built, the tree was pruned by optimising a cost parameter from adding a variable (denoted by ) with cross-validation procedure. More formally, the cost for the tree is written as follows , with " , $ , ... , " are the terminal nodes of a tree and ( $ ) is probability of terminal node to be included in the tree. To note, ( ) can be seen as the residual sum of squares in a regression model. We refer to Breiman et al. 13 for further details of CART method. We used rpart package for this tree predictive modeling 14 . The CART analysis resulted in a tree consisting of ASCL1 for both lavage and brush self-samples ( Supplementary Fig. S7 and S8 ).
The results were compared by those of logistic regression by assessing accuracy (i.e. the proportion of the number of correctly classified samples with the total number of samples) and sensitivity at given specificity, the latter being fixed by the CART result.
